Forensic botany and forensic chemistry working together: application of plant DNA barcoding as a complement to forensic chemistry-a case study in Brazil.

Recently, Brazilian Federal Police used forensic chemistry and forensic botany techniques on a case. Two packets containing fragmented plant matter were seized and sent for forensic analysis. Forensic chemistry, the gold standard for evaluating plant material suspected to contain illicit substances, did not find illicit materials. Gas chromatography coupled mass spectrometry (GC-MS) identified thujone in the botanical material. Thujone is a chemical compound naturally found in many plant species, notably Artemisia absinthium. Because doubt remained, we next used plant DNA barcoding methods. Total DNA from plant tissue fragments was extracted and five different DNA regions were amplified, sequenced, and analyzed using plant DNA barcoding methods. Genetic analysis yielded 30 good quality sequences representing five taxa. Most specimens were identified as A. absinthium. Few studies focus on practical forensic applications of plant DNA barcoding methods using a case solved in a forensic laboratory with its difficulties and limitations. To the best of our knowledge, this is the first study to report an effective joint effort of forensic chemistry and botany techniques to assess plant material in Brazil. The availability of a new technical approach for the genetic sequencing of plant species will enhance many forensic investigations and inspire similar initiatives.

Polymorphisms of the vitamin D receptor gene (FOKI, CDX2, and GATA) and susceptibility to chronic periodontitis in diabetic and non-diabetic individuals: A case-control study.

AIM: The aim of the present study was to evaluate the distribution of single-nucleotide polymorphisms (SNP) (variants FOKI [rs2228570], CDX2 [rs47908762], and GATA [rs4516035]) in the vitamin D receptor in individuals with type 2 diabetes mellitus and chronic periodontitis (DM2 + CP), CP alone, and healthy individuals, and to investigate the relationship with susceptibility to CP. METHODS: In total, 280 individuals (116 with DM2 + CP, 95 with CP alone, and 69 healthy individuals) were genotyped using real-time polymerase chain reaction with allele-specific probes. Significant differences (P < .05) were found among the groups with regard to socio-epidemiological variables (sex, marital status, income, smoking habit, and schooling) and clinical-epidemiological variables (age, number of teeth, probing depth, clinical attachment loss, gingival bleeding index, and visible plaque index). RESULTS: The C allele was significantly more frequent among the healthy individuals (34.8%) than those with DM2 + CP (23.5%) (odds ratio [OR] = .58, 95% confidence interval [CI]: . 35-.94, P = .022). Likewise, the CC allele was significantly more frequent among healthy individuals (11.6%) than those with DM2 + CP (2.6%) (OR = .17, 95% CI: .03-.79, P = .015). CONCLUSION: The results suggest that the presence of these variants could lead to a lower susceptibility to DM2 and CP. No other significant differences among groups were found for the other SNP investigated.

The influence of SLC6A3 and DRD2 polymorphisms on levodopa-therapy in patients with sporadic Parkinson's disease.

OBJECTIVES: The aim of this study was to evaluate a possible relationship between DRD2/ANKK1 (rs1800497) and SLC6A3/DAT1 (rs28363170) gene polymorphisms with the response to levodopa (L-DOPA)-therapy in patients with Parkinson's disease (PD). METHODS: One hundred and ninety-five patients with idiopathic PD were investigated. Patients were genotyped for rs1800497 and rs28363170 polymorphisms using PCR-RFLP. Logistic regression was performed to assess the association of polymorphisms with the occurrence of the chronic complications of L-DOPA therapy. KEY FINDINGS: Our results showed association between the occurrence of dyskinesia with an increased greater disease severity (P = 0.007), higher L-DOPA dose (P = 0.007) and use of dopamine agonist (P = 0.020). Moreover, there were significant protective effects for age (P = 0.004) and male subjects (P = 0.006). CONCLUSIONS: Clinical and demographic characteristics of Brazilian PD patients and differences in DRD2 and DAT1 genes may to determine individual variations in the therapeutic response to L-DOPA in the Brazilian PD patients.

Host genomic HIV restriction factors modulate the response to dendritic cell-based treatment against HIV-1.

Host genome is still poorly investigated in the context of vaccine or immunotherapy, however recently findings emphasized that it may affect the response to those treatments. In our retrospective study we evaluated the effect of HIV-1 genetic restriction factors on the response to dendritic cell (DC)-based immunotherapy in a Brazilian cohort of HIV positive (HIV+) patients that underwent a phase I clinical trial in 2004. Genomic DNA from 18 HIV+ individuals that underwent DC-based immunotherapy was analyzed for selected polymorphisms known to be associated with susceptibility to HIV-1 infection and/or AIDS progression. Allelic and genotypic distribution of the 22 polymorphisms was evaluated considering the response to the treatment. The rs11884476 SNP in PARD3B resulted associated with good response to immune treatment according to an over-dominant model. Even if functional effect of this variation is still unknown, our data suggested that it could play a role in the control of viral replication. Our findings, being aware of the limitation represented by the small number of subjects analyzed, suggest that genetic factors involved in AIDS progression could affect the response to immunotherapy, reinforcing the idea that deeper investigation on host genetic variations will be fundamental for a rational vaccine development.